MAPT and Parkinson disease: The connection of VPS35 with tau pathology in Parkinson’s disease models is intriguing, and VPS35 levels were shown to be reduced in vulnerable forebrain regions of subjects with different tauopathies, including Alzheimer’s disease, Pick’s disease and progressive supranuclear palsy.17